STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT–MET switch and cancer metastasis

Wei-Hsin Lin, Yi-Wen Chang, Min-Xiang Hong, Te-Cheng Hsu, Ko-Chuan Lee, Che Lin, Jia-Lin LeeOncogene 2020 · OpenReview

Abstract

Epithelial–mesenchymal transition (EMT)/mesenchymal–epithelial transition (MET) processes are proposed to be a driving force of cancer metastasis. By studying metastasis in bone marrow-derived mesenchymal stem cell (BM-MSC)-driven lung cancer models, microarray time-series data analysis by systems biology approaches revealed BM-MSC-induced signaling triggers early dissemination of CD133+/CD83+ cancer stem cells (CSCs) from primary sites shortly after STAT3 activation but promotes proliferation towards secondary sites. The switch from migration to proliferation was regulated by BM-MSC-secreted LIF and activated LIFR/p-ERK/pS727-STAT3 signaling to promote early disseminated cancer cells MET and premetastatic niche formation. Then, tumor-tropic BM-MSCs circulated to primary sites and triggered CD151+/CD38+ cells acquiring EMT-associated CSC properties through IL6R/pY705-STAT3 signaling to promote tumor initiation and were also attracted by and migrated towards the premetastatic niche. In summary, STAT3 phosphorylation at tyrosine 705 and serine 727 differentially regulates the EMT–MET switch within the distinct molecular subtypes of CSCs to complete the metastatic process.

Introduction

Metastasis is a complex, multi-step process that remains a primary cause of cancer-related mortality. A central paradox in this process is the requirement for cancer cells to transition between two states: the Epithelial-Mesenchymal Transition (EMT), which grants motility for dissemination, and the Mesenchymal-Epithelial Transition (MET), which restores proliferative capacity for colonization at secondary sites. While these transitions are known to be critical, the molecular "master switch" coordinating them—and the influence of the bone marrow microenvironment—has remained poorly understood. This study investigates how bone marrow-derived mesenchymal stem cells (BM-MSCs) drive these transitions in lung cancer through the differential regulation of the transcription factor STAT3.

Methods

The researchers utilized a systems biology approach to map the signaling dynamics between A549 lung cancer cells and BM-MSCs. A time-series microarray analysis tracked gene expression over 96 hours following treatment with BM-MSC conditioned medium (BM-MSC-CM). To physically separate cells based on their metastatic potential, the team employed functional fractionation using serial Transwell invasion assays, identifying "Early Responders" (highly migratory HM cells) and "Late Responders" (more epithelial/proliferative LM cells).

Time-series microarray analysis and functional fractionation of A549 cells treated with BM-MSC conditioned medium.

Key Insights: The STAT3 Toggle Switch

The study identified STAT3 as a central hub in the signaling network. Crucially, STAT3 functions as a sophisticated toggle switch depending on its phosphorylation site:

  • The "Grow" Signal (Ser727): Activation of the LIFR/p-ERK/pS727-STAT3 pathway by BM-MSC-secreted LIF promotes MET and proliferation, allowing early disseminated cancer cells (eDCCs) to settle and form a premetastatic niche.
  • The "Move" Signal (Tyr705): The IL6R/pY705-STAT3 pathway, triggered by IL-6, promotes EMT and migration, enabling a different subpopulation of cells to initiate dissemination from the primary tumor.

This sequential signaling suggests that BM-MSCs act as long-distance coordinators, secreting different factors that hit different cancer cell subpopulations at different times.

Key Results: CSC Heterogeneity and Clinical Impact

The research revealed distinct molecular subtypes of Cancer Stem Cells (CSCs) involved in different stages of metastasis. CD133+/CD83+ cells were identified as early responders that settle and grow, while CD151+/CD38+ cells respond later to initiate migration. Functional fractionation demonstrated that highly migratory (HM20) cells exhibited a clear mesenchymal signature (low CDH1, high VIM), while LM cells remained more epithelial.

Functional fractionation of invasive cells (HM1-HM20) and molecular characterization of EMT/MET markers.

Clinical data supported these findings, showing that high levels of LIFR and pS727-STAT3 correlate with advanced disease (Stage IV) and poor overall survival. Primary tumors were characterized by the "move" signal (pY705-STAT3), whereas metastatic nodules favored the "grow" signal (pS727-STAT3).

Discussion and Limitations

This work highlights the importance of targeting specific phosphorylation pathways rather than broad STAT3 inhibition. For example, targeting the LIFR/ERK axis might be a more precise way to prevent metastatic colonization. However, the study's reliance on specific lung cancer cell lines (A549, CL1-5) necessitates further validation in other metastatic cancers like breast or prostate. Additionally, while BM-MSCs are key players, the full complexity of the bone marrow niche, including immune cells and osteoblasts, warrants future investigation to fully understand the metastatic switch.

Summary updated

Abstract

Epithelial–mesenchymal transition (EMT)/mesenchymal–epithelial transition (MET) processes are proposed to be a driving force of cancer metastasis. By studying metastasis in bone marrow-derived mesenchymal stem cell (BM-MSC)-driven lung cancer models, microarray time-series data analysis by systems biology approaches revealed BM-MSC-induced signaling triggers early dissemination of CD133+/CD83+ cancer stem cells (CSCs) from primary sites shortly after STAT3 activation but promotes proliferation towards secondary sites. The switch from migration to proliferation was regulated by BM-MSC-secreted LIF and activated LIFR/p-ERK/pS727-STAT3 signaling to promote early disseminated cancer cells MET and premetastatic niche formation. Then, tumor-tropic BM-MSCs circulated to primary sites and triggered CD151+/CD38+ cells acquiring EMT-associated CSC properties through IL6R/pY705-STAT3 signaling to promote tumor initiation and were also attracted by and migrated towards the premetastatic niche. In summary, STAT3 phosphorylation at tyrosine 705 and serine 727 differentially regulates the EMT–MET switch within the distinct molecular subtypes of CSCs to complete the metastatic process.
BibTeX
@inproceedings{lin2020stat,
  author = {Wei-Hsin Lin and Yi-Wen Chang and Min-Xiang Hong and Te-Cheng Hsu and Ko-Chuan Lee and Che Lin and Jia-Lin Lee},
  title = {{STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT–MET switch and cancer metastasis}},
  booktitle = {Oncogene},
  year = {2020},
  url = {https://openreview.net/forum?id=X5yOHC32Wz},
}
Figure